Drug intelligence / Profile preview

TV-46017

Development stage: Discontinued
Lead developer: Teva Pharmaceutical Industries
Modality: Small Molecules
Administration: Inhalation

Overview

TV-46017 is a small molecule drug developed by Teva Pharmaceutical Industries for the treatment of respiratory diseases, specifically chronic obstructive pulmonary disease (COPD). It was investigated as an inhaled therapy intended to provide bronchodilation. The drug reached Phase 1 clinical trials, where its safety profile and duration of bronchodilation were evaluated in both healthy volunteers and COPD patients. Development of TV-46017 has since been discontinued.

Other names: Glycopyrronium bromideGlycopyrrolate

Targets

CHRM3 (M3)

Beyond the preview

Go deeper on TV-46017.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on TV-46017.

Explore the full profile